NEWS

WIRES

OTHER

Penny Stock Chaser Announces Investment Opinion on GFG, EK, BMS, STSI and PLX

Every trading day PennyStockChaser.com sifts through thousands of stocks to identify those that are poised and ready to move up. Penny Stock Chaser is monitoring Guaranty Financial Group Inc (NYSE:GFG), Eastman Kodak (NYSE:EK), Bernis Co Inc (NYSE:BMS), Star Scientific Inc (NASDAQ:STSI), Protalix BioTherapeutics Inc (AMEX:PLX). To receive more hot stock alerts, investors simply need to join our FREE newsletter service by visiting the following link: http://www.pennystockchaser.com/join-now/

The following stocks are expected to go higher:

Guaranty Financial Group Inc (NYSE:GFG) rose 4 percent to $0.22 in midday trading and on July 2^nd GFG move up 10% and closed on $ 0.21. The Company is a financial services holding company. Through its main operating subsidiaries, Guaranty Bank and Guaranty Insurance Services, Inc., it operates in four business segments: Commercial banking, Retail banking, Insurance agency,and Treasury, corporate and other.

Eastman Kodak (NYSE:EK) up 7% trading at $2.89 today after the Company announced today that it will release its Second-Quarter 2009 financial results on Thursday, July 30 at 7:00 A.M. Eastern Time over Business Wire and Kodak.com Investor Relations web page.

Bernis Co Inc (NYSE:BMS) is up 5% after Rio Tinto has signed an agreement to sell its Alcan Packaging Food Americas division to Bemis Company, Inc for a total consideration of US$1.2 billion of which US$ 200 million may be in the form of shares in Bemis Company, Inc.

Star Scientific Inc (NASDAQ:STSI) is up 10% trading at $0.94 on no news. Star Scientific, Inc. is a technology-oriented tobacco company with a mission to reduce toxins in tobacco leaf and tobacco smoke. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins

Protalix BioTherapeutics Inc (AMEX:PLX) move 13% to $5.15 after the Company announced today that it was approached by the U.S. Food and Drug Administration (FDA) and asked to consider submitting a treatment protocol for the use of prGCD in patients with Gaucher disease in order to address an expected shortage of the drug Cerezyme(R), a mammalian cell expressed version of glucocerebrosidase (GCD) and the only enzyme replacement therapy currently approved for Gaucher disease.

About PennyStockChaser.com

PennyStockChaser.com is an independent electronic publication that provides information on selected publicly traded companies. PennyStockChaser.com is not a registered investment advisor or broker-dealer. PennyStockChaser.com's affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

Michael Scott Jacobs, CFA, of PennyStockChaser.com is a member of the National Association of Securities Dealers, CRD number 1818665.

PennyStockChaser.com
Mike Schonberg, 1-866-469-8524
editorial@pennystockchaser.com
http://www.pennystockchaser.com